Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells 62,102 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Mark Sabag sold 62,102 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total value of $1,871,754.28. Following the sale, the insider owned 224,940 shares in the company, valued at $6,779,691.60. This represents a 21.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Teva Pharmaceutical Industries Trading Down 0.6%

Teva Pharmaceutical Industries stock traded down $0.19 during trading hours on Thursday, hitting $29.42. The stock had a trading volume of 8,738,969 shares, compared to its average volume of 9,491,616. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $33.83 billion, a price-to-earnings ratio of 24.52, a P/E/G ratio of 10.07 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The business’s 50 day simple moving average is $32.78 and its 200-day simple moving average is $26.92.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the business posted $0.71 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of several recent research reports. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Scotiabank boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Piper Sandler restated an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Phoenix Financial Ltd. lifted its stake in Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the period. National Pension Service grew its position in shares of Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after buying an additional 404,526 shares during the period. Public Sector Pension Investment Board increased its stake in shares of Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after acquiring an additional 69,000 shares in the last quarter. Oak Harvest Investment Services acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.